Having trouble accessing articles? Reset your cache.

Maximizing neoantigens

How Replimune optimized its oncolytic virus platform to combine with anti-PD-1s

In conjunction with raising $55 million in a series B round on Friday, Replimune Group Inc. unveiled details of its Immulytic oncolytic virus platform, including next-generation constructs that underpin the company’s strategy for creating multimodal partners for checkpoint inhibitors.

President and CEO Robert Coffin said Replimune launched in 2015 to create an oncolytic virus platform that maximized the ability to provoke an immune response to tumor neoantigens so they can be combined with PD-1 and PD-L1 inhibitors.

The company reunited veterans from BioVex Inc. (now part of Amgen Inc.), which created the first oncolytic virus approved in the U.S., Imlygic talimogene laherparepvec, also known as T-Vec.

“T-Vec, which we previously developed at BioVex, is the beginning of what you can do with this technology -- but not the best you can do,” Coffin told BioCentury.

Oncolytic viruses attack tumor cells both directly by killing

Read the full 1404 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers